GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction

Cancer Research

Volumn 71, Issue 24, 2011, Pages 7694-7704

  Li, Kun ^a   Ren, Chengzhen ^a   Yang, Guang ^a   Fattah, Elmoataz Abdel ^b   Goltsov, Alexei A ^a   Kim, Soo Mi ^a,d   Lee, Ju Seog ^a   Park, Sanghee ^a   Demayo, Francesco J ^b   Ittmann, Michael M ^b,c   Troncoso, Patricia ^a   Thompson, Timothy C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Chonbuk National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CASEIN KINASE IALPHA; GENE GLIOMA PATHOGENESIS RELATED PROTEIN 1; GLYCOGEN SYNTHASE KINASE 3ALPHA; MYC PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UBIQUITINATION; UPREGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASEIN KINASE IALPHA; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UBIQUITINATION;

EID: 84255191993     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1714     Document Type: Article

References (40)

1. Li L, Abdel Fattah E, Cao G, Ren C, Yang G, Goltsov AA, et al. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res 2008;68:434-43. (Pubitemid 351380069)
2. Ren C, Li L, Goltsov AA, Timme TL, Tahir SA, Wang J, et al. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol 2002;22:3345-57. (Pubitemid 34453976)
3. Ren C, Li L, Yang G, Timme TL, Goltsov A, Ren C, et al. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res 2004;64:969-76. (Pubitemid 38176899)
4. Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J, et al. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 2003;14:91-101. (Pubitemid 36418814)
5. Naruishi K, Timme TL, Kusaka N, Fujita T, Yang G, Goltsov A, et al. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther 2006;17:17.
6. Ren C, Ren CH, Li L, Goltsov AA, Thompson TC. Identification and characterization of RTVP1/GLIPR1-like genes, a novel p53 target gene cluster. Genomics 2006;88:163-72. (Pubitemid 44062273)
7. Aytekin T, Ozaslan M, Cengiz B. Deletion mapping of chromosome region 12q13-24 in colorectal cancer. Cancer Genet Cytogenet 2010;201:32-8.
8. Tam M, Lin P, Hu P, Lennon PA. Examining Hedgehog pathway genes GLI3, SHH, and PTCH1 and the p53 target GLIPR1/GLIPR1L1/GLIPR1L2 gene cluster using fluorescence in situ hybridization uncovers GLIPR1/GLIPR1L1/GLIPR1L2 deletion in 9% of patients with multiple myeloma. J Assoc Genet Technol 2010;36:111-4.
9. Rosenzweig T, Ziv-Av A, Xiang C, Lu W, Cazacu S, Taler D, et al. Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells. Cancer Res 2006;66:4139-48.
10. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999;18:3004-16. (Pubitemid 29276540)
11. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle 2008;7:592-6. (Pubitemid 351498996)
12. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008;8:976-90.
13. Wierstra I, Alves J. The c-myc promoter: still MysterY and challenge. Adv Cancer Res 2008;99:113-333. (Pubitemid 350137254)
14. Liu J, Levens D. Making myc. Curr Top Microbiol Immunol 2006;302:1-32. (Pubitemid 43273330)
15. Arnold HK, Zhang X, Daniel CJ, Tibbitts D, Escamilla-Powers J, Farrell A, et al. The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J 2009;28:500-12.
16. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell 1999;3:169-79. (Pubitemid 29292618)
17. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 2004;3:1133-7. (Pubitemid 40268631)
18. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004;6:308-18. (Pubitemid 38584820)
19. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008;8:83-93. (Pubitemid 351161321)
20. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation- dependent c-Myc protein degradation. Proc Natl Acad Sci U S A 2004;101:9085-90. (Pubitemid 38781615)
21. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-14.
22. Galletti M, Riccardo S, Parisi F, Lora C, Saqcena MK, Rivas L, et al. Identification of domains responsible for ubiquitin-dependent degradation of dMyc by glycogen synthase kinase 3beta and casein kinase 1 kinases. Mol Cell Biol 2009;29:3424-34.
23. Siddall NA, Lin JI, Hime GR, Quinn LM. Myc-what we have learned from flies. Curr Drug Targets 2009;10:590-601.
24. Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 2009;8:4032-9.
25. Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci 2009;35:161-8.
26. Taelman VF, Dobrowolski R, Plouhinec JL, Fuentealba LC, Vorwald PP, Gumper I, et al. Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 2010;143:1136-48.
27. Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal 2005;17:675-89. (Pubitemid 40250168)
28. Price MA. CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling. Genes Dev 2006;20:399-410.
29. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108:837-47. (Pubitemid 34327534)
30. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010;6:829-36.
31. Price MA, Kalderon D. Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by Glycogen Synthase Kinase 3 and Casein Kinase 1. Cell 2002;108:823-35. (Pubitemid 34327533)
32. Kim S, Park Y, Park ES, Cho JY, Izzo JG, Zhang D, et al. Prognostic biokarmers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 2010;5:e15074.
33. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008;21:1156-67.
34. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 2005;103:1186-94. (Pubitemid 40328089)
35. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
36. Cell Signaling Technology. 2003-2011. Protein Page: Myc (Human). Available from: http://www.phosphosite.org/proteinAction.do?id=947.
37. Ramsay G, Evan GI, Bishop JM. The protein encoded by the human proto-oncogene c-myc. Proc Natl Acad Sci U S A 1984;81:7742-6. (Pubitemid 15169137)
38. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51. (Pubitemid 30639518)
39. Robinson DR, Zylstra CR, Williams BO. Wnt signaling and prostate cancer. Curr Drug Targets 2008;9:571-80.
40. Takemaru KI, Ohmitsu M, Li FQ. An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics. Handb Exp Pharmacol 2008;186:261-84.